A census of amplified and overexpressed human cancer genes
By T. Santarius, J. Shipley, D. Brewer, Michael R. Stratton, C. Cooper. Nature Reviews. Cancer, 2010
596 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/9271cc9888283bd1c980b9b566b1ee368d02fed5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
In Molecular Biology
Citations in the corpus
- Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy (2010, unknown): “Our findings lend additional support to the idea that YEATS4 is probably a key amplified gene in cancer, as recently suggested through a weight-of-evidence classification scheme proposed for identifying such amplified cancer gene”
- Subclonal diversification of primary breast cancer revealed by multiregion sequencing (2015, unknown): “The panel targets genes from the Cancer Gene Census (COSMIC) 24 , genes recurrently amplified or over-expressed in cancer 22,23 and E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s candidate cancer genes such as kinases from…”
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers (2011, background): “Genes targeted by somatic copy-number alterations (SCNAs), in particular, play central roles in oncogenesis and cancer therapy [3].”
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity (2015, unknown): “Low-grade glioma (8) Melanoma (273) Thyroid (238) Colorectal (48) Lung adeno (36) Multiple myeloma (17) G466 (15) G469 (18) N581 (9) D594 (7) BRAF”
- Cyclin D as a therapeutic target in cancer (2011, background): “Cyclin D overexpression in cancer CCND1 is a well-established human oncogene: a recent census concluded that there was substantial evidence for the involvement of CCND1 amplification and overexpression in breast cancer and significant evidence for its involvement in lung cancer, melano”
- Cyclin D1, Cancer Progression and Opportunities in Cancer Treatment (2016, background): “Cancers that frequently harbor cyclin D1 genomic alterations include pancreatic cancer (∼25–82 %) [112], non-small cell lung carcinoma (∼5– 76 %) [111, 113, 114], breast cancer (∼15–70 %) [115], head and neck squamous cell carcinoma (HNSCC) (∼20–68 %) [116, 117], melanoma (∼0–65 %) [118], endometria”
- A compendium of mutational cancer driver genes (2020, unknown): “(756;3) Bladder (822;6) Hepatic cancer (1,606;9)”